BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Monday, May 19, 2014 at 11:00 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
